EirGenix Company Description
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally.
The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services.
It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage.
In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein.
EirGenix Inc. was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
Country | Taiwan |
Founded | 2012 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Lee-Cheng Liu |
Contact Details
Address: No. 101, Kangning Street New Taipei City Taiwan | |
Phone | 886 2 7708 0123 |
Website | eirgenix.com |
Stock Details
Ticker Symbol | 6589 |
Exchange | Taipei Exchange |
Fiscal Year | January - December |
Reporting Currency | TWD |
ISIN Number | TW0006589005 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Lee-Cheng Liu | Founder, President, Chief Executive Officer, CSO and Chairman |
Hsiu-Chuan Yang | Chief Financial Officer, Vice President and Manager of Corporate Governance |
Dr. Chih-Jung Chang | Vice President and Chief Operating Officer |
Dr. Thomas Schulze Ph.D. | Managing Director of EirGenix Europe GmbH |
Dr. Shang-Chung Ju | Executive Director and Chief Manufacturing Officer |
Dr. Barbara Grohmann-Izay | Vice President and CMO |